Global Meningococcal Vaccines Market by Combination-, Conjugate-, Polysaccharide Vaccines, and Forecast to 2021, New Report by iHealthcareAnalyst, Inc.
Meningococcal Vaccines Market by Meningococcal Combination Vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal Conjugate Vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); and Meningococcal Polysaccharide Vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo).
Maryland Heights, MO, April 13, 2017 --(PR.com)-- The global meningococcal vaccines market is estimated to reach US$ 4.3 Bn in 2021, expanding at a CAGR of 12.6% from 2017 to 2021, due to technological advancement and its rapid adoption worldwide.
Browse Meningococcal Vaccines Market by Meningococcal Combination Vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal Conjugate Vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); and Meningococcal Polysaccharide Vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/meningococcal-vaccines-market/
Meningococcal vaccines are now available that help protect against all three serogroups of meningococcal disease that are most commonly observed (serogroups B, C and Y), but they do not prevent all the cases. Meningococcal disease is a contagious and life threatening infection of the meninges (connective tissue surrounding the brain and spinal cord). The disease occurs worldwide with considerable geographic variability in serogroup distribution. It has the highest incidence in young children regardless of serogroup type. Currently, none of the vaccines available provide protection against all serogroups causing meningococcal disease, although there are vaccines covering a broad range of serogroups. There are three kinds of meningococcal vaccines available: Meningococcal combination vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal conjugate vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); Meningococcal polysaccharide vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo).
The global meningococcal vaccines market report estimates the market size (Revenue USD million - 2014 to 2021) based on combination vaccines, conjugate vaccines and polysaccharide vaccine and also forecasts growth trends (CAGR% - 2017 to 2021). The global meningococcal vaccines market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global meningococcal vaccines market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global meningococcal vaccines market and included in this report are Baxter International, Biomed Pvt. Ltd., GlaxoSmithKline plc, JN International Medical Corporation, Nuron Biotech, Novartis International AG, Pfizer, Inc., Serum Institute of India, Ltd., and Sanofi S.A.
1. Vaccine Type
1.1. Combination Vaccines
1.1.1. Bexsero
1.1.2. MenHibrix
1.1.3. Menitorix
1.1.4. Trumenba
1.2. Conjugate Vaccines
1.2.1. Menactra
1.2.2. MenAfriVac
1.2.3. Meningitec
1.2.4. Menjugate
1.2.5. Menveo
1.2.6. NeisVac-C
1.2.7. Nimenrix
1.2.8. NmVac4-DT
1.3. Polysaccharide Vaccines
1.3.1. Bi Meningo
1.3.2. Mencevax
1.3.3. Menomune
1.3.4. NmVac4
1.3.5. Quadri Meningo
2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World
3. Company Profiles
3.1. Baxter International, Inc.
3.2. Biomed Pvt., Ltd.
3.3. GlaxoSmithKline plc
3.4. JN-International Medical Corporation
3.5. Nuron Biotech, Inc.
3.6. Pfizer, Inc.
3.7. Sanofi SA
3.8. Serum Institute of India, Ltd.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/meningococcal-vaccines-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Browse Meningococcal Vaccines Market by Meningococcal Combination Vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal Conjugate Vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); and Meningococcal Polysaccharide Vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/meningococcal-vaccines-market/
Meningococcal vaccines are now available that help protect against all three serogroups of meningococcal disease that are most commonly observed (serogroups B, C and Y), but they do not prevent all the cases. Meningococcal disease is a contagious and life threatening infection of the meninges (connective tissue surrounding the brain and spinal cord). The disease occurs worldwide with considerable geographic variability in serogroup distribution. It has the highest incidence in young children regardless of serogroup type. Currently, none of the vaccines available provide protection against all serogroups causing meningococcal disease, although there are vaccines covering a broad range of serogroups. There are three kinds of meningococcal vaccines available: Meningococcal combination vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal conjugate vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); Meningococcal polysaccharide vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo).
The global meningococcal vaccines market report estimates the market size (Revenue USD million - 2014 to 2021) based on combination vaccines, conjugate vaccines and polysaccharide vaccine and also forecasts growth trends (CAGR% - 2017 to 2021). The global meningococcal vaccines market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global meningococcal vaccines market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global meningococcal vaccines market and included in this report are Baxter International, Biomed Pvt. Ltd., GlaxoSmithKline plc, JN International Medical Corporation, Nuron Biotech, Novartis International AG, Pfizer, Inc., Serum Institute of India, Ltd., and Sanofi S.A.
1. Vaccine Type
1.1. Combination Vaccines
1.1.1. Bexsero
1.1.2. MenHibrix
1.1.3. Menitorix
1.1.4. Trumenba
1.2. Conjugate Vaccines
1.2.1. Menactra
1.2.2. MenAfriVac
1.2.3. Meningitec
1.2.4. Menjugate
1.2.5. Menveo
1.2.6. NeisVac-C
1.2.7. Nimenrix
1.2.8. NmVac4-DT
1.3. Polysaccharide Vaccines
1.3.1. Bi Meningo
1.3.2. Mencevax
1.3.3. Menomune
1.3.4. NmVac4
1.3.5. Quadri Meningo
2. Geography (Region, Country)
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World
3. Company Profiles
3.1. Baxter International, Inc.
3.2. Biomed Pvt., Ltd.
3.3. GlaxoSmithKline plc
3.4. JN-International Medical Corporation
3.5. Nuron Biotech, Inc.
3.6. Pfizer, Inc.
3.7. Sanofi SA
3.8. Serum Institute of India, Ltd.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/meningococcal-vaccines-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Contact
Categories